Description
Fuarte presents itself in the form of white to off-white, round, flat, beveled-edge tablets. Each tablet is imprinted with ‘D3’ on one side, signifying its distinctive identity. Notably, every dispersible tablet contains 500 mg of deferasirox, the active ingredient essential to its therapeutic function.
Comprehensive Ingredients
In addition to deferasirox, Fuarte incorporates several auxiliary substances to facilitate its formulation. These substances include lactose monohydrate (derived from cow’s milk), crospovidone CL, povidone K30, sodium lauryl sulfate, microcrystalline cellulose (Type 101), colloidal silicon dioxide (200), and magnesium stearate. This comprehensive composition contributes to the medication’s overall efficacy.
Medical Applications
Fuarte is a potent solution for the management of excessive iron overload, primarily arising from regular blood transfusions. This medication extends its efficacy across various age groups, including adults, adolescents, and children aged 2 years and over. Moreover, this tablet finds utility in treating patients with thalassemia syndromes associated with iron overload, even if they do not receive blood transfusions. In this scenario, it can be administered to adults, adolescents, and children aged 10 years and over.
How Fuarte Works?
Fuarte operates as an iron chelator, a category of medications specialized in managing iron overload. Its mode of action involves binding to excess iron within the body, often referred to as iron overload. Subsequently, this tablet facilitates the removal of this surplus iron, primarily through feces. This pivotal process alleviates the complications associated with iron overload.
Dosage Guidelines
To maximize the therapeutic benefits of this tablet , it is administered orally after dispersing it in water. The appropriate dosage is determined by calculating the patient’s weight in kilograms and then rounding it to the nearest whole tablet dose. The primary objective of iron chelation therapy with Fuarte is to eliminate the excess iron acquired through transfusions and reduce the existing iron load as required.
Packaging
Fuarte tablets are thoughtfully packaged in blister packs, with each pack containing 28 tablets. This packaging design ensures ease of access and convenient storage while maintaining the medication’s integrity.
Additional Information
It is important to note that Fuarte is subject to additional monitoring to swiftly identify any emerging safety information. Individuals who are prescribed this medication can actively participate in this process by promptly reporting any side effects they may experience. Detailed instructions on how to report side effects can be found in Section 4 of the provided information.
Adherence to Guidance
Individuals using this tablet are reminded that this medication is prescribed for their specific needs and should not be shared with others. Should you require medical attention from another healthcare provider during the course of Fuarte usage, it is imperative to inform them about your ongoing medication regimen. Adherence to the instructions outlined in the provided leaflet is crucial, including strict compliance with recommended dosage levels.
Consulting Healthcare Professionals
For any additional queries or concerns, individuals are encouraged to consult their doctor or pharmacist. These healthcare professionals can offer valuable guidance and address any specific questions related to Fuarte.
The recommended dosage of Fuarte Suda Dagilabilen Tablet 500 Mg is contingent upon the condition being treated:
- For Chronic Iron Overload due to Blood Transfusions (Transfusional Hemosiderosis): Fuarte is suitable for children and adults aged 2 years and over. Treatment initiation is advised when approximately 20 units (equivalent to about 100 mL/kg) of erythrocyte suspension have been transfused, or when clinical monitoring reveals chronic iron overload (typically indicated by serum ferritin levels exceeding 1000 micrograms/L).
- For Chronic Iron Overload in Patients with Non-Transfusion-Dependent Thalassemia Syndromes: Fuarte is recommended for use in patients aged 10 years and over.
It is important to calculate doses in milligrams per kilogram (mg/kg) and round them to the nearest whole tablet dose. The ultimate goal of iron chelation therapy is to eliminate excess iron acquired through transfusions and adjust the existing iron load as necessary.
Adapting Dosages
For adults receiving more than 14 mL/kg per month (equivalent to approximately more than 4 units) of erythrocyte suspension and aiming to reduce the body’s iron load, initiating treatment with 30 mg/kg of Fuarte per day may be considered. Conversely, for adults receiving less than 7 mL/kg per month (equivalent to approximately less than 2 units) of erythrocyte suspension and aiming to maintain the body’s iron load at the current level, starting with 10 mg/kg of this tablet per day may be contemplated.
Transition from Deferoxamine
Patients currently benefiting from deferoxamine treatment can transition to Fuarte with a simplified process. The starting dose of Fuarte should be numerically half the dose of deferoxamine. For example, a patient receiving 40 mg/kg of deferoxamine (or an equivalent) per day for 5 days a week should initiate Fuarte treatment with a starting dose of 20 mg/kg per day.
Monitoring Progress
To gauge the patient’s response to treatment and minimize the risk of excessive chelation, it is recommended to monitor serum ferritin levels on a monthly basis.
A Final Overview
In conclusion, Fuarte Suda Dagilabilen Tablet 500 Mg stands as a crucial player in the realm of iron overload management. Its efficacy spans a broad spectrum of conditions, catering to diverse age groups. While precision in dosages is vital, healthcare providers remain the guiding force in steering individuals towards improved well-being.
Table: Key Information
| Aspect | Details |
|---|---|
| Active Ingredient | Deferasirox |
| Dosage Form | White to Off-White, Round, Flat, Beveled-Edge Tablets |
| Dosage | Customized Based on Condition and Patient Weight (mg/kg) |
| Precautions | Reporting Side Effects, Individualized Treatment Plans, Monitoring Serum Ferritin Levels, Compliance with Guidance |
| Packaging | Blister Packs Containing 28 Tablets |
| Additional Information | Medication Under Additional Monitoring, Personalized Prescription, Adherence to Instructions, Consultation with Healthcare Professionals |
Reviews
There are no reviews yet.